PAXX: A Potential Drug Target and Biomarker for Neurodegenerative Diseases

Target Name: PAXX

NCBI ID: G286257

PAXX

PAXX: A Potential Drug Target and Biomarker for Neurodegenerative Diseases

PAXX (Paralog of XRCC4 and XLF) is a protein that is expressed in the brain and is known for its role in the regulation of neural circuits. The XRCC4 gene is a tumor suppressor gene that has been implicated in the development of various diseases, including cancer. The XLF gene is a tumor suppressor gene that has also been implicated in the development of various diseases. PAXX is a protein that is produced by the translation of the XRCC4 gene. In this article, we will discuss the potential implications of PAXX as a drug target or biomarker.

Structure and Function

PAXX is a 21-kDa protein that is expressed in the brain. It has a molecular weight of 41 kDa and a calculated pI of 6.9. PAXX is a single transmembrane protein that contains a catalytic domain, a transmembrane domain, and an N-terminus. The catalytic domain is responsible for the catalytic activity of PAXX, while the transmembrane domain is responsible for its stability and functions as a protein. The N-terminus of PAXX is a cytoplasmic tail that is involved in the formation of a complex with other proteins.

PAXX is involved in the regulation of neural circuits, including the regulation of neuronal excitability and the regulation of synaptic plasticity. It has been shown to play a role in the regulation of synaptic plasticity, including the regulation of the strengthening of synapses and the regulation of the dynamics of synaptic vesicles. It is also involved in the regulation of neuronal excitability, including the regulation of action potentials and the regulation of neurotransmitter release.

PAXX is a potential drug target because of its involvement in the regulation of neural circuits. The development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, is thought to be caused by the dysfunction of neural circuits. Therefore, targeting PAXX as a drug target could potentially lead to the development of new treatments for these diseases.

PAXX is also a potential biomarker for the diagnosis and monitoring of neurodegenerative diseases. The dysfunction of neural circuits is a common feature of neurodegenerative diseases, and the regulation of these circuits is often disrupted in these diseases. Therefore, measuring the expression of PAXX could potentially be a useful biomarker for the diagnosis and monitoring of neurodegenerative diseases.

Discovery and Therapeutic Potential

The discovery of PAXX as a drug target or biomarker is a promising development in the field of neurodegenerative diseases. The identification of a potential drug target and biomarker for a neurodegenerative disease can lead to the development of new treatments that can slow the progression of the disease and improve the quality of life for patients.

PAXX has been shown to be involved in the regulation of neural circuits, including the regulation of neuronal excitability and the regulation of synaptic plasticity. Therefore, drugs that target PAXX may have potential therapeutic effects on neurodegenerative diseases.

One potential approach to targeting PAXX is the use of small molecules that can modulate its activity. Small molecules that can modulate the activity of PAXX may be identified through a variety of screening techniques, including high-throughput screening and bioinformatics analysis. These small molecules can then be tested for their potential therapeutic effects on neurodegenerative diseases.

Another potential approach to targeting PAXX is the use of antibodies that can specifically target it. antibodies that can specifically target PAXX and modulate its activity can then be used to treat neurodegenerative diseases. These antibodies can be generated using various techniques, including monoclonal antibodies and yeast-based approaches.

Conclusion

PAXX is a protein that is expressed in the brain and is involved in the regulation of neural circuits. Its regulation of neural circuits makes it a potential drug target and biomarker for the development of

Protein Name: PAXX Non-homologous End Joining Factor

Functions: Non-essential DNA repair protein involved in DNA non-homologous end joining (NHEJ); participates in double-strand break (DSB) repair and V(D)J recombination (PubMed:25574025, PubMed:25670504, PubMed:25941166, PubMed:27705800). May act as a scaffold required for accumulation of the Ku heterodimer, composed of XRCC5/Ku80 and XRCC6/Ku70, at double-strand break sites and promote the assembly and/or stability of the NHEJ machinery (PubMed:25574025, PubMed:25670504, PubMed:25941166). Involved in NHEJ by promoting the ligation of blunt-ended DNA ends (PubMed:27703001). Together with NHEJ1/XLF, collaborates with DNA polymerase lambda (POLL) to promote joining of non-cohesive DNA ends (PubMed:30250067, PubMed:25670504). Constitutes a non-essential component of classical NHEJ: has a complementary but distinct function with NHEJ1/XLF in DNA repair (PubMed:27705800). Able to restrict infection by herpesvirus 1 (HSV-1) via an unknown mechanism (PubMed:29144403)

The "PAXX Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PAXX comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets